Aims/hypothesis Mutations in BSCL2/seipin cause Berardinelli-Seip congenital lipodystrophy (BSCL), a rare recessive disorder characterised by near absence of adipose tissue and severe insulin resistance. We aimed to determine how seipin deficiency alters glucose and lipid homeostasis and whether thiazolidinediones can rescue the phenotype.
Introduction
Adipose tissue plays a key role in whole-body energy homeostasis. The expansion of adipose tissue leads to obesity and related metabolic complications; lipodystrophies (disorders characterised by a partial or complete lack of adipose tissue) are also associated with severe metabolic disturbances. Among the lipodystrophies, Bernardinelli-Seip congenital lipodystrophy (BSCL) displays the most severe phenotype with a combination of insulin resistance, liver steatosis and hypertriglyceridaemia [1] . BSCL is an autosomal recessive disease linked to mutations in either BSCL2, encoding seipin [2] , or AGPAT2, encoding 1-acylglycerol-3-phosphate O-acyltransferase-β [3] . In a few cases, BSCL is due to mutations in the genes encoding either caveolin-1 [4] or cavin-1 [5] , both involved in the formation of caveolae [6] .
The function of seipin is still unclear. Some studies indicate that seipin is involved in adipogenesis, lipid metabolism and lipid droplet (LD) biogenesis and maintenance [7] [8] [9] [10] [11] [12] . Notably, knocking down seipin with short hairpin RNA alters terminal adipocyte differentiation in C3H10T1/2 mesenchymal stem cells [13] or 3 T3-L1 adipocyte cell lines, with a downregulation of transcription factors involved in adipogenesis and of their downstream lipogenic target genes [13, 14] . The effect of peroxisome proliferator-activated receptor-γ (PPARγ) agonists, such as thiazolidinediones (TZDs), on the altered adipogenesis linked to seipin deficiency remains controversial and cell-type dependent. In 3T3-L1 cells, pioglitazone was reported to partially rescue the defective adipogenic process due to seipin depletion [14] . In contrast, the same group recently reported that pioglitazone was unable to fully restore the adipogenic programme in seipindeficient (Bscl2 −/− ) mouse embryonic fibroblast (MEF)-derived adipocytes [15] . A major breakthrough in the field of seipin came recently, with the demonstration by two independent groups that Bscl2 −/− mice develop severe lipodystrophy, validating the hypothesis that seipin has a critical role in adipocyte differentiation in vivo [15, 16] . In these two models, Bscl2
−/− mice presented with a massive, but not complete, loss of white adipose tissue (WAT). These two models displayed several discrepancies concerning their metabolic phenotype.
In one study, Bscl2 −/− mice displayed normal plasma glucose concentrations in the random-fed state [16] , while in the second, they were frankly hyperglycaemic [15] . In addition, lipid metabolism in these two models raises several questions. First, in contrast to the human phenotype [1] , Bscl2 −/− mice do not display fasting hypertriglyceridaemia.
Second, while these mice exhibit liver steatosis [15, 16] , the hepatic lipid metabolism has not been explored with in vivo functional studies and therefore remains poorly understood. The aim of the present study was to unravel how seipin deficiency leads to the metabolic complications associated with BSCL, with a special focus on liver steatosis and dyslipidaemia. To address these issues, we generated a new Bscl2
−/− mouse model and performed a complete metabolic phenotyping of glucose and lipid homeostasis. Considering therapeutic intervention in BSCL patients, we assessed whether in vivo treatment with TZDs could reverse the phenotype of Bscl2 −/− mice.
Methods

Generation of Bscl2
−/− mice and colony maintenance The targeting construct contains a short arm, 1210-bp fragment in the third intron of Bscl2 synthesised by PCR using primers: 5′-GCACAGTGGCACACATCTAT-3′ and 5′-AGAACTTCACTTGCCTCAGC-3′, and a long fragment (XbaI-HpaI, including exons 7-11) excised from a phage clone obtained from an SV-129 mouse genomic library (kindly offered by J. Weissenbach, CEA/IG Centre National de Séquençage, Evry, France). They were inserted into plasmid pG23 (Genoway, Lyons, France) with a neomycin cassette (NEO) in between. The gene map is shown in electronic supplementary material (ESM) Fig. 1 . Using ES cell-line E14, Bscl2 was modified by homologous recombination, by which exons 4-6 were replaced by NEO. Recombination was screened by PCR and confirmed by Southern blotting. Chimeric mice were obtained by blastocyst injection (Genoway) and germline transmission was confirmed. Mice were backcrossed with C57BL/6 J for ten generations and heterozygotes were inbred. Mice were housed in a temperature-controlled room (22°C) with a 12 h light-dark cycle. Food and water were freely available. The ethics committees of the local animal facilities approved all animal protocols used in this study. For the in vivo pioglitazone treatment, mice were fed with chow diet (Safe, Augy, France) supplemented with pioglitazone (Actos; Takeda, Puteaux, France) at a concentration of 300 mg/kg (45 mg kg −1 day −1 ). [17] .
Microscanner analyses Adipose tissue distribution was analysed using the Inveon X-ray micro-computed tomography (CT) system (Inveon; Siemens, Erlangen, Germany). Mice were scanned at 9, 13, 17 and 22 weeks of age using the same variables. The X-ray source tube voltage was set at 45 keV with a constant 500 μA current for 320 ms. Rotation of 1°was used to generate images of 110 μm pixel resolution. Three-dimensional reconstructions and analysis of adipose tissue variables were performed using COBRA (Siemens) and ITK-Snap software (www.itksnap.org), respectively [18] .
Glucose and insulin tolerance tests Food was removed 6 h before the initiation of the intra-peritoneal glucose tolerance test (IPGTT) or the insulin tolerance test (ITT). At time 0, a single dose of glucose (2 g/kg) or insulin (0.75 U/kg Actrapid; Novo Nordisk, Chartres, France) was administered by i.p. injection and blood glucose levels were monitored using a glucometer (Freestyle Papillon; Abbot, Rungis, France) on 2.5 μl samples collected from the tail. Energy expenditure measurement O 2 consumption, CO 2 production, activity and food and water intake were measured using the physiocage system (Panlab, Barcelona, Spain). Mice were acclimatised for 48 h, and measurements were performed during the following 48 h.
In vivo lipid metabolism
RNA analysis Total RNA from tissues was purified using Trizol (Life technology, les Ulis, France) according to the manufacturer's instructions. Total RNA from cell samples was purified with the NucleoSpin RNA II (Macherey Nagel, Hoerdt, France). Total RNA (500 ng) was reversetranscribed and real-time quantitative PCR was performed using the TaqMan 7900 Sequence Detection System (Applied Biosystems, Warrington, UK). Primers were designed using the Primer Express 3.1 software (Life Technology, les Ulis, France, sequence available on request). Results are represented as arbitrary units indicating relative expressions by calculation based on the comparative C t (also called ΔC t ) methods after normalisation to cyclophilin or 36B4 as the reference genes (indicated in the figure legend where applicable).
Isolation and culture of MEFs Bscl2
+/− pregnant female mice were killed at 12.5-14.5 days post-coitum, embryos were collected and MEFs were isolated. Adipocyte differentiation, oil red O staining and lipolysis assay were performed as previously described [19, 20] . For Bodipy staining, cells were grown on glass coverslips, fixed in 4% paraformaldehyde and stained with Bodipy 493/503 (Life technology) for 30 min.
Lipid extraction and measurement Cell and tissue samples were homogenised in lysis buffer mixed with four volumes of chloroform/methanol (2/1, vol./vol.). After being shaken for 1 h, samples were centrifuged 20 min at 500g. The organic (lower) phase was placed in a new tube, evaporated under N 2 and resuspended in the appropriate volume of isopropanol. A 10 μl volume was evaporated in a 96-well plate for determination of TAG content.
Statistical analysis All data were reported as means±SEM. Data sets were analysed for statistical significance using the non-parametric Mann-Whitney U test or, when mentioned in the figure legend, two-way ANOVA analysis; *p<0.05, **p<0.01 and ***p<0.001.
Results
Bscl2
−/− mice are severely lipodystrophic and diabetic We generated Bscl2 −/− mice by gene targeting based on the mutation identified in BSCL2 in patients with BSCL (i.e. a large deletion, including exons 4-6) [2, 21] (ESM Fig. 1a ). Because homozygous Bscl2 −/− male mice were sterile, the colony was maintained by crossing heterozygous Bscl2
mice. Genotypes at embryonic day 12 followed a mendelian pattern (24% Bscl2 +/+ , 53% Bscl2
, and 23% Bscl2 −/− ; n= 117 embryos) but the ratio of Bscl2 −/− mice surviving after weaning was only 18% (n = 126, 3-week-old mice), suggesting an increased perinatal death. Consistent with the human BSCL phenotype, seipin deficiency led to a severe generalised lipodystrophy in mice. X-ray micro-CT analysis showed that 2-month-old male Bscl2 −/− mice displayed a near-total lipoatrophy (Fig. 1a) .
However, total body weight did not differ between genotypes during ageing (ESM Fig. 1b ). Dissection revealed that peri-gonadal fat pads were completely absent, with a genuine organomegaly of the liver, intestine, kidneys and epididymal canal in Bscl2 −/− mice (Fig. 1b) . Liver weight was twofold increased in Bscl2 −/− compared with wild-type mice (Table 1) . A reduced, but still measurable, residual mass of mesenteric and inguinal WAT was present in Bscl2 −/− mice.
Interscapular brown adipose tissue (BAT) was reduced, but still present, in 2-month-old Bscl2 −/− mice. In accordance with lipodystrophy, circulating levels of both leptin and adiponectin were significantly reduced (Fig. 1c, d ) and daily food intake was increased by 37% (Fig. 1e) . Bscl2 −/− mice displayed random-fed hyperglycaemia starting at 9 weeks of age and worsening with ageing ( Fig. 1f) , while fasting plasma glucose remained unchanged (data not shown). Fasting insulinaemia was significantly increased in Bscl2 −/− mice (Fig. 1g ). IPGTT and ITT demonstrated that Bscl2 −/− mice exhibited both glucose intolerance and severe insulin resistance ( Fig. 1h , i).
Seipin deficiency accelerates liver clearance of TRL
Although hypertriglyceridaemia is a common feature of patients with BSCL [1], 2-month-old Bscl2 −/− mice displayed a 40% decrease in plasma TAG in both the fasted and random-fed state (Fig. 2a) . Plasma NEFA levels were also decreased by 40% in Bscl2 −/− mice in the fasted state, but not in the random-fed state (Fig. 2b) . In contrast, seipin deficiency did not alter fasted total cholesterol levels (Fig. 2c) . The cholesterol-lipoprotein profile revealed a weak decrease in LDL-cholesterol and a slight increase in large and apolipoprotein E-rich HDLcholesterol in Bscl2 −/− mice (Fig. 2d ).
We measured VLDL-TAG secretion rate using the lipoprotein lipase inhibitor tyloxapol, which blocks TAG clearance from the bloodstream [17] . As shown in Fig. 2e , the hepatic VLDL-TAG secretion rate was similar in both genotypes. In addition, intestinal chylomicron production, measured after intravenous injection of tyloxapol followed by an oral gavage of olive oil, did not vary between genotypes (Fig. 2f) . Then, we studied the clearance of both VLDL and chylomicrons by labelling TRL on fatty acids and protein moieties using [ 3 H]palmitate (lipid moiety) (Fig. 2g) and 125 I (protein moiety) (Fig. 2h) . Two minutes after injection, the radioactivity in plasma was decreased by 20% and 60%, respectively in wild-type mice and in Bscl2 −/− mice, indicating an increased TRL clearance in Bscl2 −/− mice. The difference was maintained over 30 min.
Consistently, the liver content of 3 H and 125 I was increased in Bscl2 −/− mice (Fig. 2i, j) .
Thiazolidinediones partially restore the function of Bscl2
−/− adipocytes in vitro To identify pharmacological strategies for improving the metabolic complications associated with lipodystrophy, we studied the effect of TZDs on Bscl2
−/− adipocyte function. In MEFs isolated from wild-type and Bscl2 −/− mice, Oil Red O staining revealed that both rosiglitazone and pioglitazone increased the number of lipid-loaded cells (Fig. 3a) . Rosiglitazone increased TAG content by twofold in Bscl2 −/− MEFs (Fig. 3b) . Next, we measured the expression levels of early and late markers of adipocyte differentiation during adipogenesis [22] . Cebp mRNA levels were reduced in Bscl2 −/− MEFs, suggesting that seipin has an impact on early adipogenesis (Fig. 3c) . The induction of Pparg (Fig. 3d) and Cebpa (ESM Fig. 2 ) mRNA was lower in Bscl2 −/− mice 2 days after the beginning of adipocyte differentiation. In mature adipocytes (day 9), Pparg, Ap2 (also known as Fabp4, encoding adipocyte fatty acid binding protein) and Adipoq (encoding adiponectin) expression levels were reduced by more than twofold in Bscl2 −/− cells ( Fig. 3d-f) . While rosiglitazone was able to fully restore Pparg and Adipoq expression levels at day 4 in Bscl2 −/− cells (Fig. 3d, f) , it only partially restored Ap2 mRNA levels throughout the adipogenic programme (Fig. 3e) . As LDs play a key role in the control of lipid storage, we analysed their morphology in both genotypes using Bodipy 493/503 coloration. While wild-type cells displayed multiple round and well-delimited small LDs, Bscl2 −/− MEFs displayed large and often unique LDs (Fig. 3g) . Rosiglitazone restored a multiple/well-defined pattern of (Fig. 3h) . In contrast, isoprenaline (isoproterenol)-stimulated lipolysis was similar in both genotypes. Rosiglitazone tended to reduce this increase in basal lipolysis rate in Bscl2 −/− cells without reaching significance.
Pioglitazone improves insulin sensitivity in vivo in Bscl2
−/− mice In a next step, we assessed whether a TZD could improve metabolic variables in vivo in Bscl2 −/− mice. Onemonth-old Bscl2 −/− male mice were fed a pioglitazoneenriched (300 mg/kg) diet for 9 weeks. Pioglitazone normalised both random-fed plasma glucose and fasting insulin levels and significantly improved insulin sensitivity assessed by ITT (Fig. 4a-d) . Pioglitazone also tended to improve glucose tolerance without reaching statistical Fig. 3a) . Pioglitazone increased plasma levels of adiponectin and leptin (Fig. 4e, f) and induced a threefold increase in the weight of residual mesenteric and inguinal fat pads (Table 1) . While Cebpb expression was not impaired, Pparg, Lep (encoding leptin), Adipoq, Plin1 (encoding perilipin A) and Lipe (encoding hormone-sensitive lipase [HSL]) mRNA levels were reduced in the inguinal fat pad of Bscl2 −/− compared with wild-type mice (Fig. 4g ).
Pioglitazone significantly increased Ap2 and Adipoq mRNA levels in the Bscl2 −/− inguinal fat pad, while it did not induce Lep expression, despite its effects on circulating levels of leptin. We observed the same pattern of gene expression in the mesenteric residual WAT, but the effect of the TZD was less marked. Indeed, neither Ap2 nor Adipoq mRNA levels were induced by pioglitazone in Bscl2 −/− or wild-type mice (ESM Fig. 3b ). 
Pioglitazone increases energy expenditure in Bscl2
−/− mice Mice were individually placed into metabolism cages to measure the O 2 consumption, CO 2 production and energy expenditure (Fig. 5a-c) . Under basal/untreated conditions, seipin deficiency was associated with a decrease in energy expenditure without any change in physical activity (Fig. 5d ). Interestingly, pioglitazone was able to fully restore the metabolic profile of Bscl2 −/− mice.
These data show that pioglitazone increases the metabolic rate in Bscl2 −/− mice.
Pioglitazone reduces liver steatosis and restores normal TRL clearance in Bscl2 −/− mice As pioglitazone is known to improve liver steatosis [23] , we then studied its effect on hepatic lipid metabolism. Both liver weight (Table 1) and TAG content (Fig. 6a) were strongly reduced in Bscl2 −/− mice upon dietary pioglitazone treatment. This was associated with a total body weight loss (Table 1) . Circulating FGF-21 levels were increased in untreated Bscl2 −/− mice compared with wild-type mice (Fig. 6b ). In accordance with the reduction in liver steatosis, pioglitazone treatment restored normal FGF-21 levels in Bscl2 −/− mice.
To understand the mechanism involved in the reduction of liver steatosis, we reperformed TRL clearance experiments after 9 weeks of pioglitazone treatment. As previously described [24] , pioglitazone treatment accelerated TRL clearance in wild-type mice. In contrast, in Bscl2 −/− mice pioglitazone treatment reduced TRL clearance to a normal rate (Fig. 6c) , and consequently lowered the hepatic lipid uptake (Fig. 6d) . Normalisation of triglyceridaemia in TZD- −/− mice was consistent with this finding (ESM Fig. 4 ). Pparg mRNA expression, which was induced in the steatotic liver of untreated Bscl2 −/− mice, was also drastically reduced following pioglitazone treatment (ESM Fig. 5a ). Similarly, mRNA levels of the lipogenic transcription factor Srebp1c (also known as Srebf1, encoding sterol response element binding protein-1c ) and its target genes, Fas (also known as Fasn) and Scd1 (encoding stearoyl coenzyme A desaturase 1), which were upregulated in Bscl2 −/− mice, were significantly reduced upon pioglitazone treatment (ESM Fig. 5b-d) . In contrast, pioglitazone treatment did not alter the expression of genes involved in NEFA oxidation, such as Cpt1a (encoding carnitine palmitoyltransferase 1) (ESM Fig. 5f ). Finally, mRNA levels of both Cd36 and Ldlr (encoding the LDL receptor [LDLr]) were reduced in pioglitazone-treated Bscl2 −/− mice (ESM Fig. 5g, h ). The protein level of LDL receptor (LDLr) was also reduced in pioglitazone-treated Bscl2 −/− mice, whereas the scavenger receptor (CD36) protein remained unchanged (Fig. 6e) .
Discussion
Based on the characterisation of a new Bscl2 −/− mouse model, the present work gives further insights into the metabolic function of seipin, which plays a major part in the pathogenesis of BSCL in humans [2] . First, we confirm that seipin deficiency leads to severe lipodystrophy, profound insulin resistance and ultimately diabetes, perfectly reflecting observations made in patients with BSCL. Second, we demonstrate that Bscl2 −/− mice exhibit an unexpected hypotriglyceridaemia due to an increase in hepatic TRL and NEFA uptake, leading to severe liver steatosis. Last, we show that in vivo treatment with a TZD (i.e. pioglitazone) improves insulin sensitivity, metabolic rate and liver steatosis in Bscl2 −/− mice.
It is now accepted that seipin is crucial for full adipogenesis [13, 14] but the effect of pharmacological activation of PPARγ by TZDs on adipocyte differentiation in seipin-deficient cells remains controversial [14, 15] . In our study, TZD normalised the expression levels of PPARγ and its target gene, Adipoq, while it only partially rescued the Ap2 mRNA levels in Bscl2 −/− MEFs. Accordingly, in human fibroblasts isolated from a patient with BSCL, pioglitazone induced the expression of adipogenic markers such as AP2 and lipoprotein lipase [25] . Consistent with a beneficial effect of TZDs on adipocyte function, intracellular TAG concentration was increased and LD morphology pattern was partially normalised in treated Bscl2
MEFs. An increase in basal, but not β 3 -agonist-stimulated lipolysis was observed in Bscl2 −/− MEFs and this default also likely contributes to the inability of seipin-deficient adipocytes to store lipids. Recently, Chen et al reported that this increased lipolysis was dependent on cAMP protein kinase A activation and could be corrected by a lipase inhibitor [15] . We confirm here that TZDs failed to correct this default in lipolysis [15] . Taken together, these results suggest that seipin deficiency has two major consequences for adipocyte function: (1) a default in the late adipogenic programme, which is largely improved by TZDs and (2) an intrinsic default in lipolysis rate, which is resistant to TZDs.
One of the key findings is that pioglitazone can efficiently improve insulin sensitivity, random-fed glucose levels and liver steatosis in Bscl2 −/− mice. This effect is surprising since TZDs failed to improve glucose homeostasis in A-ZIP/F-1 mice, which totally lack WAT [26] . This suggests that pioglitazone likely improves insulin sensitivity in Bscl2 −/− mice by promoting adipose tissue expansion (thereby reducing lipotoxicity) and adiponectin secretion from residual fat depots. To further explore seipin function in adipocytes, we analysed the gene expression profile in residual mesenteric and inguinal fat pads from Bscl2 −/− mice.
In contrast to our findings in Bscl2 −/− MEFs, there was no defect in the expression of Cebpb, a transcription factor involved in the early stage of pre-adipocyte determination. However, the expression of several key players in adipogenesis (Pparg), endocrine function (Lep and Adipoq) and lipolysis (Hsl and Plin1) was severely decreased, confirming the impairment in late adipogenesis observed in vitro. Interestingly, pioglitazone treatment was able to induce expression of Ap2 and Adipoq in vivo in Bscl2 −/− residual subcutaneous WAT, thereby leading to an increase in circulating levels of adiponectin. Pioglitazone treatment also increased plasma levels of leptin in Bscl2 −/− mice despite a lack of effect at the transcriptional level. The increase in leptin concentrations could be linked to WAT mass increment, although we cannot exclude the possibility that leptin originates from another tissue. It should be noted that the improvement in adipocyte function mice. In contrast, in wild-type mice, pioglitazone treatment increased TRL clearance without affecting the hepatic lipid uptake as this effect is usually mediated by VLDL receptor upregulation in WAT [24] . This suggests an additional mechanism to explain the effect of pioglitazone on TRL clearance in the context of seipin deficiency. One hypothesis is that the upregulation of hepatic LDLr expression in Bscl2 −/− mice may contribute to the altered lipid phenotype.
The LDLr is a key player in hepatic uptake of VLDL [27] and its expression is increased in the liver of insulin-resistant mice [28] . This induction has been attributed to SREBP-1c overexpression in response to hyperinsulinaemia, without any change in SREBP-2 expression [28, 29] . In liver from Bscl2 −/− mice, LDLr expression was indeed increased and pioglitazone treatment was able to decrease LDLr at similar levels to wild-type mice. The decrease in insulinaemia observed in pioglitazone-treated Bscl2 −/− mice likely contributes to the decrease in SREBP-1c and LDLr levels and, subsequently, to normalisation of liver TRL clearance. The decreased expression of lipogenic genes that follows SREBP-1c expression might also contribute to the improvement of liver steatosis. Alternatively, pioglitazone treatment might also reduce liver steatosis by promoting lipid use, since it increases metabolic rate and energy expenditure in Bscl2 −/− mice. This effect could result from the increase in adiponectinaemia, which was shown to induce NEFA oxidation in liver and to reduce hepatic TG content [23] . Accordingly, the total plasma ketone body concentration was increased in pioglitazone-treated Bscl2 −/− mice (data not shown). This finding apparently contrasts with previous studies of TZD treatment in animal models of lipodystrophy. Chao et al have shown that in A-ZIP/F-1 mice, TZD treatment increased rather than decreased liver steatosis [26] . Using liver-specific PPARγ-deficient mice, Gavrilova et al demonstrated that this effect was strictly dependent on the activation of hepatic PPARγ [30] . Although we cannot rule out a cellautonomous effect of seipin in liver, our results suggest that the beneficial reduction of liver steatosis observed in Bscl2 −/− mice treated with pioglitazone is sustained by the activation of adipose PPARγ in the residual fat depots. Our results open new perspectives for the treatment of patients with BSCL and are in accordance with the findings of a study in which rosiglitazone improved insulin sensitivity and decreased HbA 1c in a patient with BSCL2. Rosiglitazone also increased plasma leptin levels while moderately decreasing liver lipogenic enzymes [25] . However, dual X-ray absorptiometry analysis failed to reveal a significant increase in fat mass upon rosiglitazone treatment, likely due to a lack of sensitivity of the method. This raises the question of the presence of remaining fat pads in BSCL patients, although the presence of WAT in BSCL2 patients has been detected by different techniques (dual energy X-ray densitometry or magnetic resonance imaging) [31, 32] . Actually, recombinant leptin injection is the gold-standard therapy in adults [33, 34] and children [35] with BSCL. However, some BSCL patients progressively develop leptin resistance due to the production of leptin antibodies [36] . Additional clinical studies are warranted to determine whether TZDs represent a valid alternative option for the treatment of BSCL.
In conclusion, our study confirms that Bscl2 −/− mice exhibit a severe lipodystrophy associated with diabetes, liver steatosis and unexpected hypotriglyceridaemia. This specific lipid phenotype, due to an increased uptake of TRL and NEFA by the liver, offers a new model of liver steatosis. Finally, we demonstrate that the metabolic complications associated with BSCL can be partially rescued by pioglitazone in vivo, reinforcing the observation by Victoria et al [25] that TZD might be a therapeutic option for BSCL patients. 
